A new master trial for testing investigational drugs in acute myeloid leukemia has benefited from input from the US FDA and could enable speedy approvals in small, molecularly-defined subsets of patients with the disease, according to the Leukemia & Lymphoma Society (LLS), the trial's sponsor.
The society designed the "Beat AML" master protocol to use genomic insights to energize development of new therapies for AML, a form of blood cancer that is notoriously difficult to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?